EPCs lysate-sensitized DC vaccine derived from tumor microenvironment and preparation method thereof

A tumor microenvironment and lysate technology is applied in the field of DC vaccine sensitized by EPCs lysate derived from tumor microenvironment and its preparation field, which can solve the problems of unsatisfactory effect and other problems, and achieve the enhancement of anti-tumor angiogenesis and inhibition of tumor blood vessels. generated effect

Inactive Publication Date: 2019-10-08
ZHEJIANG CANCER HOSPITAL
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

All of the above methods have played a certain role in angiogenesis, but they are not specific methods for EPCs, so the effect is not satisfactory
At present, there is no specific method for EPCs in the world

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • EPCs lysate-sensitized DC vaccine derived from tumor microenvironment and preparation method thereof
  • EPCs lysate-sensitized DC vaccine derived from tumor microenvironment and preparation method thereof
  • EPCs lysate-sensitized DC vaccine derived from tumor microenvironment and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] 1. Isolation of bone marrow mononuclear cells and culture of endothelial progenitor cells (EPCs)

[0039] 1.2.2.1 Isolation of mouse bone marrow mononuclear cells and culture of endothelial progenitor cells (EPC)

[0040] 1.2.2.1.1 Isolation of mouse bone marrow mononuclear cells

[0041] 1) C57BL / 6 mice were sacrificed (collecting blood for later use),

[0042] 2) Aseptically take the tibia and femur, and use serum-free medium (DMEM) to quickly wash the bone marrow into a centrifuge tube until the washing solution is clear.

[0043] 3) Repeatedly blow and beat the washing solution, and then add it slowly into the test tube containing the lymphocyte separation solution according to the ratio of 1:1 along the tube wall with a dropper.

[0044] 4) Centrifuge at 2000r / mi for 20min at 20°C,

[0045] 5) The gray-white cloud layer cells between the lymphocyte separation liquid and the culture medium obtained by centrifugal separation are bone marrow mononuclear cells.

[...

Embodiment 2

[0155] Example 2: Expression of CD80, CD86, and MHCII in DC cells sensitized by LLC-EPCs

[0156] experimental method:

[0157] The aforementioned cells (mature DC cells obtained in Example 1) were digested with trypsin and washed once with PBS. Block with PBS containing 5% FBS or 5% BSA for 30 minutes on ice. Wash once with PBS, resuspend with PBS containing 0.5% BSA, and adjust the cell density to 2×106 cells / mL. Take 100 μL of cells for staining, add isotype control and anti-CD86, CD80, MHC-II antibodies respectively according to the dilution ratio in the instructions. Incubate at 4 degrees for 30 minutes. Immature dendritic cells were used as negative control. Centrifuge and remove supernatant. Wash once with PBS. Add 400 μL PBS to resuspend, flow on the machine.

[0158] Solution preparation:

[0159] 5%BSA:2.5gBSA+50mLPBS

[0160] 0.5%BSA:0.25gBSA+50mLPBS

[0161] Experimental results:

[0162] see Figure 3-5 , the results showed that the expressions of CD80...

Embodiment 3

[0163] Example 3: Effect of LLC-EPC-DC on Proliferation of Mixed Lymphocytes

[0164] experimental method:

[0165] Isolation of T lymphocytes:

[0166] 1) Take the spleen of the mouse under aseptic conditions, and grind it through a 40um filter;

[0167] 2) Collect the cell suspension and add 3ml of erythrocyte lysate;

[0168] 3) Wash cells twice with PBS, 1200rpm, 5min, resuspend and count;

[0169] 4) Take 1x107 cells and add 40ul buffer;

[0170] 5) Add 5ul Biotin-Antibody Cocktail, 4°C for 5min;

[0171] 6) Add 30ul buffer, add 10ul Anti-Biotin Microbeads, and treat at 4°C for 5min;

[0172] 7) Centrifuge at 1200rpm for 5min, add 500ul buffer to pass through the column;

[0173] 8) Collect the cells and count under the counting plate;

[0174] Buffer: PBS containing 0.5% BSA, 2mM EDTA.

[0175] Mixed lymphocyte reaction and CCK-8 proliferation detection:

[0176] 1) Collect the prepared DC cells, add 25mg / L mitomycin, and treat at 37°C for 45min

[0177]2) Afte...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a EPCs lysate-sensitized DC vaccine derived from tumor microenvironment and a preparation method thereof. The prepared EPCs lysate-sensitized DC vaccine derived from tumor microenvironment is safe and effective, the body produces immunity against EPCs in the tumor microenvironment, the local EPCs is eliminated, and the tumor blood vessels can be destroyed. The DC vaccine can effectively kill EPCs, the tumor angiogenesis can be inhibited, the endothelial cells can be killed, and anti-tumor angiogenesis can be strengthened.

Description

[0001] (1) Technical field [0002] The invention relates to a DC vaccine sensitized by EPCs lysate derived from tumor microenvironment and a preparation method thereof. [0003] (2) Background technology [0004] Angiogenesis plays an important role in tumor growth and metastasis. Anti-angiogenic therapy has become an important anti-tumor treatment strategy. Autoendothelial cell vaccine can significantly induce the body's immunity, and can inhibit tumor angiogenesis, thereby inhibiting tumor growth. [0005] EPCs are precursors of endothelial cells. It can not only carry out angiogenesis to generate new blood vessels, but also differentiate into endothelial cells and integrate into tumor sprouting new blood vessels to participate in angiogenesis. EPCs can also secrete a variety of pro-angiogenic factors to promote angiogenesis in a paracrine manner [8] . Selective targeting of EPCs will provide an important means to prevent tumor metastasis, progression and improve the pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/00A61P35/00C12N5/0784
CPCA61K39/0011A61P35/00C12N5/0639C12N2502/28C12N2502/30
Inventor 赵宏光王黎芳陈文虎杜蓬
Owner ZHEJIANG CANCER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap